Search
Ragweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnRagweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by su...
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
AVX-001
go.drugbank.com/drugs/DB19194InvestigationalAVX-001 is under investigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult
Eribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated ...
Products: Eribulin EVER Pharma 0,44 mg/ml InjektionslösungCefditoren
go.drugbank.com/drugs/DB01066ApprovedCefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
ZYC300
go.drugbank.com/drugs/DB04986InvestigationalZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
Bezlotoxumab
go.drugbank.com/drugs/DB13140ApprovedBezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce th...
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Categories: Serotonin Receptor Agonists, Serotonin 5-HT1 Receptor AgonistsRidogrel
go.drugbank.com/drugs/DB01207ExperimentalHowever, there currently are no clinical indications for preferential use of ridogrel over aspirin.